6 results match your criteria: "Institute for inflammatory and infectious diseases[Affiliation]"
Nat Rev Drug Discov
November 2024
Institute for inflammatory and infectious diseases, INSERM UMR1291 - CNRS UMR505, Toulouse, France.
In neuroinflammatory diseases, systemic (blood-borne) leukocytes invade the central nervous system (CNS) and lead to tissue damage. A causal relationship between neuroinflammatory diseases and dysregulated cytokine networks is well established across several preclinical models. Cytokine dysregulation is also observed as an inadvertent effect of cancer immunotherapy, where it often leads to neuroinflammation.
View Article and Find Full Text PDFVaccines (Basel)
September 2022
Department of Medicine, Université Paul Sabatier, 31400 Toulouse, France.
Clin Infect Dis
November 2022
Department of Nephrology and Organ Transplantation, Toulouse University Hospital, Toulouse, France.
The immunogenicity of the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccine was improved by the administration of a third dose. The aim of our retrospective study was to assess the evolution of binding and neutralizing antibody concentration until 3 months after the third dose in a large cohort of solid organ transplant (SOT) patients (n = 872). At 1 month after the third dose, anti-SARS-CoV-2 antibodies were detected by means of enzyme-linked immunosorbent assay tests in 578 patients (66.
View Article and Find Full Text PDFJAMA Netw Open
November 2021
Université Paul Sabatier, Toulouse, France.
This case series study assesses whether a fourth dose of a SARS-CoV-2 messenger RNA (mRNA)–based vaccine is associated with improved anti–SARS-CoV-2 antibody response in solid organ transplant recipients in France.
View Article and Find Full Text PDFTranspl Infect Dis
December 2021
Toulouse Institute for Inflammatory and Infectious Diseases (Infinity), Inserm, CNRS, UPS, Université de Toulouse, Toulouse, France.